My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Bristol-Myers Squibb (NY:BMY)

54.20 +0.88 (+1.64%)

Streaming Delayed Price Updated: 3:52 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

84 85 Next >

Beat the S&P 500 With This Cash-Gushing Dividend Stock ↗

April 01, 2025

Via The Motley Fool

Topics Intellectual Property Stocks

BMY: A High-Yielding Drug Stock With Great Growth Potential ↗

April 01, 2025

Bristol-Myers Squibb Co. traces its corporate beginnings back to 1887. Today, the company is a leader in developing innovative drugs like Eliquis for stroke prevention and Opdivo for cancer...

Via Talk Markets

Topics Stocks / Equities

Exploring the top movers within the S&P500 index during today's session. ↗

March 31, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

Via Chartmill

5 Ways to Prepare for AI’s ‘Tower of Terror’ Moment ↗

March 30, 2025

As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025.

Via InvestorPlace

Topics Artificial Intelligence Economy Government

50-Year-Old Early Retiree Making $175,000 in Dividends Shares Portfolio - 'Now I Spend on Travel, Cars and Doing What I Want' ↗

March 28, 2025

Via Benzinga

Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...

March 28, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

March 28, 2025

From Bristol Myers Squibb

Via Business Wire

The 5-Letter Word Every Investor Should Memorize to Win in 2025 ↗

March 27, 2025

As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025.

Via InvestorPlace

Topics Economy World Trade

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

March 27, 2025

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

3 Deeply Discounted Dividend Stocks to Buy Today ↗

March 27, 2025

Via The Motley Fool

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

March 27, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors ↗

March 26, 2025

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer.

Via Benzinga

1 Large-Cap Stock on Our Watchlist and 2 to Brush Off

March 26, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Topics Retirement

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

March 24, 2025

Via Benzinga

BRISTOL-MYERS SQUIBB CO (NYSE:BMY): good value for what you're paying. ↗

March 24, 2025

BRISTOL-MYERS SQUIBB CO may be an undervalued stock option. NYSE:BMY retains a strong financial foundation and an attractive price tag.

Via Chartmill

The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry ↗

March 21, 2025

In this video lesson, I review the overall market and a new swing position for Monday's session.

Via Talk Markets

Topics ETFs Stocks / Equities

10 Health Care Stocks Whale Activity In Today's Session ↗

March 21, 2025

Via Benzinga

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

2 High-Yield Dividend Stocks That Are Bargain Buys Right Now ↗

March 20, 2025

Via The Motley Fool

Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) suited for dividend investing? ↗

March 18, 2025

Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) is a Top Pick for Dividend Investors.

Via Chartmill

Friday's session: top gainers and losers in the S&P500 index ↗

March 14, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer ↗

March 14, 2025

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained efficacy.

Via Benzinga

These S&P500 stocks are gapping in today's session ↗

March 14, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends.

Via Chartmill

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

March 14, 2025

From Bristol Myers Squibb

Via Business Wire

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst ↗

March 13, 2025

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Via Benzinga

Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

March 13, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol-Myers Squibb Co Chart Analysis ↗

March 12, 2025

Technical analysis of the stock chart for BMY.

Via Talk Markets

Topics Stocks / Equities

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)

March 11, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

March 11, 2025

Via Benzinga

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal ↗

March 11, 2025

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

84 85 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.